AIDS

Linda B. Cottler, PhD, will receive the Marian W. Fischman Memorial Lectureship Award at the 72nd annual meeting of the College of Problems of Drug Dependence. The award was established to recognize the contributions of outstanding women scientists in drug abuse research. 

HIV infection or the treatments used to control it are prematurely aging the brain, researchers at Washington University School of Medicine in St. Louis and the University of California-San Diego have found. Blood flow in the brains of HIV patients is reduced to levels normally seen in uninfected patients 15 to 20 years older.

New HIV therapies have contributed to a decrease in AIDS deaths, but physicians suspected the more potent medications led to symptoms characteristic of metabolic syndrome. However, now researchers at the School of Medicine have found that the rate of metabolic syndrome in HIV-infected patients is virtually identical to that in uninfected people.

New HIV therapies have contributed to a decrease in AIDS deaths, but physicians suspected the more potent medications led to symptoms characteristic of metabolic syndrome. However, now researchers at Washington University School of Medicine in St. Louis have found that the rate of metabolic syndrome in HIV-infected patients is virtually identical to that in uninfected people. Furthermore, the type or duration of HIV therapy did not affect the rate of metabolic syndrome.

Sustiva is the brand name for efavirenz.The largest detailed, prospective clinical study of the mental side effects of a potent anti-AIDS drug, efavirenz, has revealed that the anxiety, dizziness, “funny feelings” and vivid dreams triggered by the drug fade away within a month, possibly clearing the way for more widespread use. Efavirenz is the first drug from its class that lasts long enough to be taken once a day, and that makes it a potentially valuable drug for AIDS treatment.

Sustiva is the brand name for efavirenz.The largest detailed, prospective clinical study of the mental side effects of a potent anti-AIDS drug, efavirenz, has revealed that the anxiety, dizziness, “funny feelings” and vivid dreams triggered by the drug fade away within a month, possibly clearing the way for more widespread use. Efavirenz is the first drug from its class that lasts long enough to be taken once a day, and that makes it a potentially valuable drug for AIDS treatment, according to scientists at the AIDS Clinical Trials Unit (ACTU) at Washington University School of Medicine in St. Louis.

Researchers are trying to reduce the number of pills needed by AIDS patients.The public perception of AIDS treatment — a cocktail of many different pills taken several times a day — has largely been erased in the U.S. thanks to advances in drug design and delivery. Many patients are able to keep sufficiently high medication levels in their bodies with once-daily doses. Now researchers in an international collaborative that includes the WUSM Aids Clinical Trials Unit have begun an ambitious new study to see if this treatment paradigm can be implemented in Third World countries.

Researchers are trying to reduce the number of pills needed by AIDS patients.The public perception of AIDS treatment — a cocktail of many different pills taken several times a day and sometimes even in the middle of the night — has largely been erased in the United States thanks to advances in drug design and delivery. Although textbook treatment guidelines still call for patients to take a few AIDS medications twice a day, many patients in industrialized countries are now able to keep sufficiently high medication levels in their bodies with once-daily doses. Now researchers in an international collaborative that includes the Aids Clinical Trials Unit (ACTU) at Washington University School of Medicine in St. Louis have begun an ambitious new study to see if this treatment paradigm can be implemented in Third World countries.

Mildred Lane Kemper Art Museum”Inside Out Loud”This spring, more than 30 campus and community partners will join the Mildred Lane Kemper Art Museum at Washington University in St. Louis to present close to 70 events relating to women’s health. Events — which range from exhibitions, concerts and theatrical performances to lectures, seminars and health screenings — are held in conjunction with the museum’s Inside Out Loud: Women’s Health in Contemporary Art, the first major exhibition dedicated to the topic, which will be on view Jan. 21 to April 24.

Hannah Wilke, “Intra-Venus #4, February 19, 1992,” (1992-93)Women’s bodies — nude, adorned, eroticized, abstracted — figure prominently in the history of art. Yet the art of women’s health is shockingly new. In January, the Mildred Lane Kemper Art Museum at Washington University in St. Louis will present Inside Out Loud: Visualizing Women’s Health in Contemporary Art, the first major museum-level exhibition dedicated to the topic. The show tracks the emergence of women’s health in American art from the early 1980s to the present, and includes approximately 50 artworks in a variety of traditional and cutting-edge media by more than 30 internationally known artists and artists’ groups.